Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
M.D. Anderson Cancer Center
Primary Objective:
• To determine the feasibility and turnaround of clinical WES and transcriptome sequencing
Secondary Objectives:
* To determine the frequency of actionable DNA and RNA alterations
* To determine the concordance of DNA and RNA alterations
* To determine the frequency of molecularly matched therapy
* To determine the feasibility of identifying mechanism(s) of acquired resistance with genomic profiling
* To determine the feasibility of molecularly matched therapy to acquired resistance alterations
Exploratory Objectives:
* To determine the feasibility of prioritizing targets with precision analytics
* To determine clinical outcomes in patients receiving molecularly matched therapy
* To determine the role of additional emerging diagnostic technologies
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Patient Eligibility:
1. Male/female patients who are at least 18 years of age on the day of informed consent signing.
2. Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy.
3. Provision of written informed consent for the study.
You may not be if
1\. None
Clareo Health | Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma
